In CRC, the combination of a PI3K/mTOR inhibitor (PF-04691502/PF-502) and a MEK blocker (PD-0325901/PD-901) has demonstrated enhanced anti-proliferative effects [1518]. Here, PIK3CA is linked to colorectal carcinoma.